Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use
Liposomal Doxorubicin and nab-Paclitaxel: Nanoparticle Cancer Chemotherapy in Current Clinical Use
复制标题
DOI：
10.1007/978-1-60761-609-2_26
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Staal, Stephen
中科院分区：
文献类型：
--
作者：
Gaitanis, Alexander;Staal, Stephen
脂质体阿霉素和白蛋白结合型紫杉醇是传统癌症化疗药物的纳米颗粒制剂，其在纳米颗粒修饰前后具有丰富的临床经验。与其母体化合物相比，其药代动力学、药效学、疗效和毒性的改变对于基于纳米颗粒的疗法的未来发展具有指导意义。在这篇文章中，我们回顾了这些药物的现状，强调了母体化合物的纳米颗粒制剂引起的临床行为的改变。
Liposomal doxorubicin and nab-paclitaxel arc nanoparticle formulations of traditional cancer chemotherapy drugs which have ample clinical experience both pre- and post-nanoparticle modification. The alterations in pharmacokinetics, pharmacodynamics, efficacy, and toxicity compared with their parent compounds are instructive for future development of nanoparticle-based therapies. In this article we review the current status of these agents, emphasizing the alterations in clinical behavior resulting from the nanoparticle formulation of the parent compound.